Immuron
Manufacturing · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
62 Lygon St L 3, Carlton South, Victoria...Phone Number
+61 388924854Website
www.immuron.com.auRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Immuron
Founded in 1994, Immuron is a commercial and clinical-stage publicly listed Australian bio pharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron is located in AustraliaExplore more
Immuron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immuron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immuron
Product Launch: Get notified when Immuron launches new products
Check out if Immuron is spiking on competitors!
Earning: See what the market has to say on Immuron recently announced quarterly report
Check if Immuron has recently received funding, and reach out quickly before it becomes old news!
Click to see if Immuron had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Immuron has new funding data
Immuron, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Immuron
Compare insights from companies similar to Immuron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immuron is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immuron is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immuron.
Immuron financials insights
Gather financial insights about Immuron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Stock Offering
$6.1M
2020
Other Financing Round
$20M
Immuron Tech Stack
A closer look at the technologies used by Immuron
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Project
Medical Research, Pharmaceuticals, Clinical Operations
Immuron News & Media
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Immuron
Sign Up For FreeTo access detailed company insights
Founded in 1994, Immuron is a commercial and clinical-stage publicly listed Australian bio pharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron is located in Australia... Read More
